STRO: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Revenue	90,837	-
Personnel-related expenses	66,680	-
Outside services	55,077	-
Preclinical research and clinical development expenses	5,623	-
Laboratory supplies	9,201	-
Facility and maintenance expenses	11,129	-
Equipment and office-related expenses	13,768	-
Travel-related expenses	654	-
Restructuring and related costs	49,023	-
Operating expenses	211,155	-
Loss from operations	-120,318	-
Non-cash interest expense related to the sale of future royalties	28,661	-
Interest income	7,717	-
Interest and other income (expense), net	-3,073	-
Non-operating loss	-24,017	-
Loss before provision for income taxes	-144,335	-
Income tax expense	-11	-
Net loss	-144,324	-87,467
Depreciation and amortization	5,700	3,800
Accretion of discount on marketable securities	2,904	2,149
Stock-based compensation	12,353	10,801
Non-cash lease expenses	4,336	2,841
Realized gain on sale of equity securities	0	0
Non-cash interest expense on deferred royalty obligation	28,661	18,991
Other	-460	-303
Accounts receivable	-4,694	-617
Prepaid expenses and other assets	-14,374	-6,421
Accounts payable	-3,043	-5,726
Accrued compensation	343	-1,141
Accrued expenses and other liabilities	3,631	7,112
Deferred revenue	-69,584	-63,449
Change in operating lease liability	-5,493	-3,561
Net cash used in operating activities	-150,796	-112,607
Purchases of marketable securities	260,911	170,973
Maturities of marketable securities	251,266	135,750
Sales of marketable securities	37,467	22,805
Proceed from sale of equity securities	0	-
Purchases of equipment and leasehold improvements	1,511	1,260
Net cash provided by investing activities	26,311	-13,678
Proceeds from sales of common stock, net of issuance costs	0	0
Proceeds from sales of common stock to ipsen biopharmaceuticals, inc. (usa)	0	0
Payment of debt	0	0
Proceeds from exercise of common stock options	1	0
Taxes paid related to net shares settlement of restricted stock units	265	240
Proceeds from employee stock purchase plan	372	246
Net cash provided by financing activities	108	6
Net (decrease) increase in cash, cash equivalents and restricted cash	-124,377	-126,279
Cash and cash equivalents at beginning of period	191,162	-
Cash and cash equivalents at end of period	66,785	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

STRO: the cashflow